-
With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline
Wednesday, February 7, 2018 - 3:37pm | 484Read More...Gilead Sciences, Inc. (NASDAQ: GILD) announced fourth-quarter results Tuesday that revealed better-than-expected top- and bottom-line numbers — but the guidance was lackluster. The Analyst Bank of America Merrill Lynch analyst Ying Huang reiterated a Neutral rating on Gilead shares and...
-
Gilead Defends Hepatitis C Treatments On Reports Of Side Effects
Thursday, January 26, 2017 - 9:18am | 485Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) appear to be unaffected by reports that call into question the safety of hepatitis C drugs. The stock was trading higher by 0.47 percent at $72.25 ahead of Thursday's stock market open. According to Stat News, reports were filed with the U.S. Food and...
-
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Wednesday, January 18, 2017 - 11:40am | 453Read More...Orphan drugs, drugs intended to prevent, diagnose or treat rare diseases/disorders, are huge sellers for the pharmaceutical industry. NPR, citing data from EvaluatePharma, noted that seven of the 10 best-selling drugs in the United States throughout 2015 were given an orphan drug status. The main...
-
Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price
Monday, November 14, 2016 - 5:57pm | 291Read More...Gilead Sciences, Inc. (NASDAQ: GILD) recently reported a Q3 EPS miss, driven by lower than expected sales of its hepatitis C drugs Harvoni and Sovaldi. The poor performance may have been in response to increasing competition from companies like AbbVie Inc (NYSE: ABBV) and Merck & Co., Inc. (...
-
Gilead Sciences Price Target Trimmed Following A Sobering Q3
Wednesday, November 2, 2016 - 12:59pm | 249Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower Wednesday after the company's third quarter results fell short of Wall Street's expectations. Following the earnings report, Brian Abrahams of Jefferies lowered the price target to $91 from $95. The analyst noted his Buy...
-
Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings
Wednesday, July 27, 2016 - 9:12am | 379Read More...Barclays remains Overweight on Gilead Sciences, Inc. (NASDAQ: GILD) on valuation and franchise stability, despite reporting disappointing second-quarter results on the heels of hepatitis C drug Harvoni's continued sales declines. Harvoni, Sovaldi Sales for Harvoni plunged about 29 percent to $2.56...
-
Gilead Vs. Merck: What To Know
Monday, March 7, 2016 - 4:19pm | 357Read More...Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (NYSE: MRK) on Monday stepped into court again, trying to settle a dispute regarding the validity of the latter's '499 and '712 patents, which Gilead’s Hepatitis C treatments Sovaldi/Harvoni were found to infringe...
-
Will Merck Encroach On Gilead's Harvoni Territory?
Tuesday, February 23, 2016 - 12:36pm | 363Read More...Slingshot Insights recently conducted an interview with Dr. Bruce Bacon, Professor of Internal Medicine at Saint Louis University School of Medicine about the impact that Merck & Co., Inc. (NYSE: MRK)’s Zepatier will have on the HCV market, particularly when it comes to Gilead Sciences...
-
Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.
Tuesday, February 2, 2016 - 6:17pm | 200Read More...Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily. Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89...
-
Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law'
Wednesday, January 27, 2016 - 3:16pm | 259Read More...According to The Boston Globe, Massachusetts Attorney General Maura Healey wrote a letter to Gilead Sciences, Inc. (NASDAQ: GILD) which suggested her office could initiate legal action. The Boston Globe noted that Healey's letter was dated January 22 and delivered to Gilead's CEO John...
-
Gilead Sciences Tumbles; Unconfirmed Reports Of Drug Pricing Changes In Japan
Wednesday, January 20, 2016 - 1:07pm | 125Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent at $87.87 on Wednesday following an unconfirmed report by Pharma Japan, a pharmaceutical industry news site in Japan. According to Pharma Japan, Gilead's Sovaldi and Harvoni are among a small handful of...
-
High Drug Prices Put Gilead Under Fire From Senate Committee
Wednesday, December 2, 2015 - 9:39am | 391Read More...The Wall Street Journal highlighted a U.S. Senate report on Gilead Sciences, Inc. (NASDAQ: GILD) saying that the pharmaceutical giant knew high prices for its Hepatitis C drug would put the medicine out of reach for many patients that needed the treatment. The company priced its Solvaldi...
-
Gilead Sciences: Here's What A Bull And A Bear Are Saying
Wednesday, July 29, 2015 - 10:34am | 483Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading higher by more than 4 percent Wednesday after the company reported better-than-expected earnings for its second quarter. Here are opposing views of what two of Wall Street's top analysts are saying. Bank Of America: Long-Term...
-
Keep An Eye On These 8 After-Hours Movers
Tuesday, July 7, 2015 - 8:18am | 368Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were up 0.42 percent in after-hours Monday on relatively high volume, after gaining 0.54 percent over the trading session. The rise was driven by the approval of its hepatitis C virus (HCV) drug Harvoni in Japan. Among the biggest gainers after the...
-
Gilead Still A 'Buy' After Harvoni Approval In Japan, Maxim Proclaims
Monday, July 6, 2015 - 10:04am | 238Read More...In a report published Monday, Maxim analyst Jason Kolbert maintained a Buy rating and $127 price target on Gilead Sciences, Inc. (NASDAQ: GILD), while mentioning that Harvoni had received approval in Japan. A majority of the population in Japan is genotype 1, a group for which Harvoni has...
